nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Doxorubicin—prostate cancer	0.331	1	CbGbCtD
Deferoxamine—XDH—Effects of Nitric Oxide—AOX1—prostate cancer	0.0251	0.223	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—TXNRD2—prostate cancer	0.00998	0.0886	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—SEPP1—prostate cancer	0.00461	0.041	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—VIMP—prostate cancer	0.00461	0.041	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—TXNRD2—prostate cancer	0.00422	0.0375	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—NFE2L2—prostate cancer	0.00404	0.0359	CbGpPWpGaD
Deferoxamine—XDH—Effects of Nitric Oxide—NOS3—prostate cancer	0.00397	0.0353	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—SERPINA3—prostate cancer	0.00392	0.0348	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—GPX3—prostate cancer	0.00385	0.0342	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—RFK—prostate cancer	0.00369	0.0328	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—PRDX2—prostate cancer	0.00297	0.0264	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—NQO1—prostate cancer	0.00292	0.0259	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—UMPS—prostate cancer	0.00267	0.0237	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—SOD2—prostate cancer	0.00225	0.02	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—CYP1A1—prostate cancer	0.00212	0.0188	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—GPX3—prostate cancer	0.00163	0.0145	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—MPO—prostate cancer	0.00151	0.0134	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—GGT1—prostate cancer	0.00115	0.0102	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—TYMS—prostate cancer	0.00105	0.00936	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—SOD2—prostate cancer	0.00095	0.00843	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—MTHFR—prostate cancer	0.000836	0.00743	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—ICAM1—prostate cancer	0.000731	0.00649	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—INS—prostate cancer	0.000665	0.00591	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—SERPINE1—prostate cancer	0.000611	0.00542	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—PTGS2—prostate cancer	0.000533	0.00474	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—HAO1—prostate cancer	0.000518	0.0046	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PSAT1—prostate cancer	0.000422	0.00375	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CBR1—prostate cancer	0.000422	0.00375	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ADI1—prostate cancer	0.000422	0.00375	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—TST—prostate cancer	0.000422	0.00375	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GRHL1—prostate cancer	0.000422	0.00375	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CSAD—prostate cancer	0.000422	0.00375	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CKMT2—prostate cancer	0.000393	0.00349	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—UGT2B15—prostate cancer	0.000393	0.00349	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—UGT2B17—prostate cancer	0.000393	0.00349	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GRHPR—prostate cancer	0.000393	0.00349	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—NAGLU—prostate cancer	0.000369	0.00328	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—AOX1—prostate cancer	0.000369	0.00328	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTM3—prostate cancer	0.000369	0.00328	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—RFK—prostate cancer	0.000369	0.00328	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—SULT2B1—prostate cancer	0.000369	0.00328	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—MBTPS1—prostate cancer	0.000369	0.00328	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PGAM2—prostate cancer	0.000369	0.00328	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—AMACR—prostate cancer	0.00035	0.00311	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CYP3A43—prostate cancer	0.00035	0.00311	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—DEGS1—prostate cancer	0.00035	0.00311	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—NAT1—prostate cancer	0.00035	0.00311	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—SRD5A2—prostate cancer	0.00035	0.00311	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—HSD17B1—prostate cancer	0.000334	0.00296	CbGpPWpGaD
Deferoxamine—Vomiting—Goserelin—prostate cancer	0.000304	0.000546	CcSEcCtD
Deferoxamine—Pain—Mitoxantrone—prostate cancer	0.000302	0.000542	CcSEcCtD
Deferoxamine—Angiopathy—Capecitabine—prostate cancer	0.000302	0.000542	CcSEcCtD
Deferoxamine—Bradycardia—Prednisone—prostate cancer	0.000302	0.000542	CcSEcCtD
Deferoxamine—Vomiting—Conjugated Estrogens—prostate cancer	0.000301	0.000541	CcSEcCtD
Deferoxamine—Urticaria—Estradiol—prostate cancer	0.000301	0.000541	CcSEcCtD
Deferoxamine—Immune system disorder—Capecitabine—prostate cancer	0.000301	0.00054	CcSEcCtD
Deferoxamine—Mediastinal disorder—Capecitabine—prostate cancer	0.0003	0.000539	CcSEcCtD
Deferoxamine—Abdominal pain—Estradiol—prostate cancer	0.0003	0.000538	CcSEcCtD
Deferoxamine—Body temperature increased—Estradiol—prostate cancer	0.0003	0.000538	CcSEcCtD
Deferoxamine—Headache—Goserelin—prostate cancer	0.0003	0.000538	CcSEcCtD
Deferoxamine—Erythema—Docetaxel—prostate cancer	0.000299	0.000537	CcSEcCtD
Deferoxamine—XDH—Metabolism—B4GALT4—prostate cancer	0.000297	0.00264	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—HPGD—prostate cancer	0.000297	0.00264	CbGpPWpGaD
Deferoxamine—Arrhythmia—Capecitabine—prostate cancer	0.000297	0.000534	CcSEcCtD
Deferoxamine—Headache—Conjugated Estrogens—prostate cancer	0.000297	0.000533	CcSEcCtD
Deferoxamine—Hallucination—Prednisone—prostate cancer	0.000295	0.00053	CcSEcCtD
Deferoxamine—Anaphylactic shock—Etoposide—prostate cancer	0.000294	0.000528	CcSEcCtD
Deferoxamine—Infection—Etoposide—prostate cancer	0.000292	0.000524	CcSEcCtD
Deferoxamine—Connective tissue disorder—Prednisone—prostate cancer	0.000291	0.000523	CcSEcCtD
Deferoxamine—XDH—Selenium Micronutrient Network—IL6—prostate cancer	0.000291	0.00258	CbGpPWpGaD
Deferoxamine—Blood creatinine increased—Doxorubicin—prostate cancer	0.00029	0.000522	CcSEcCtD
Deferoxamine—Erythema—Capecitabine—prostate cancer	0.00029	0.00052	CcSEcCtD
Deferoxamine—Asthma—Epirubicin—prostate cancer	0.00029	0.00052	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000289	0.000519	CcSEcCtD
Deferoxamine—Thrombocytopenia—Etoposide—prostate cancer	0.000288	0.000517	CcSEcCtD
Deferoxamine—Muscle spasms—Docetaxel—prostate cancer	0.000288	0.000517	CcSEcCtD
Deferoxamine—Tachycardia—Etoposide—prostate cancer	0.000287	0.000515	CcSEcCtD
Deferoxamine—Eosinophilia—Epirubicin—prostate cancer	0.000287	0.000515	CcSEcCtD
Deferoxamine—Skin disorder—Etoposide—prostate cancer	0.000285	0.000513	CcSEcCtD
Deferoxamine—Nausea—Goserelin—prostate cancer	0.000284	0.00051	CcSEcCtD
Deferoxamine—Nausea—Conjugated Estrogens—prostate cancer	0.000281	0.000505	CcSEcCtD
Deferoxamine—Urticaria—Mitoxantrone—prostate cancer	0.000281	0.000504	CcSEcCtD
Deferoxamine—XDH—Metabolism—TNFRSF21—prostate cancer	0.00028	0.00248	CbGpPWpGaD
Deferoxamine—Hypersensitivity—Estradiol—prostate cancer	0.000279	0.000502	CcSEcCtD
Deferoxamine—Abdominal pain—Mitoxantrone—prostate cancer	0.000279	0.000501	CcSEcCtD
Deferoxamine—Body temperature increased—Mitoxantrone—prostate cancer	0.000279	0.000501	CcSEcCtD
Deferoxamine—Muscle spasms—Capecitabine—prostate cancer	0.000278	0.0005	CcSEcCtD
Deferoxamine—Eye disorder—Prednisone—prostate cancer	0.000277	0.000497	CcSEcCtD
Deferoxamine—Hypotension—Etoposide—prostate cancer	0.000275	0.000493	CcSEcCtD
Deferoxamine—Vision blurred—Capecitabine—prostate cancer	0.000273	0.00049	CcSEcCtD
Deferoxamine—XDH—Metabolism—MTAP—prostate cancer	0.000272	0.00242	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CYP7B1—prostate cancer	0.000272	0.00242	CbGpPWpGaD
Deferoxamine—Dysuria—Epirubicin—prostate cancer	0.000271	0.000486	CcSEcCtD
Deferoxamine—Angiopathy—Prednisone—prostate cancer	0.000269	0.000483	CcSEcCtD
Deferoxamine—Pruritus—Estradiol—prostate cancer	0.000268	0.000482	CcSEcCtD
Deferoxamine—Asthma—Doxorubicin—prostate cancer	0.000268	0.000481	CcSEcCtD
Deferoxamine—Leukopenia—Docetaxel—prostate cancer	0.000268	0.000481	CcSEcCtD
Deferoxamine—Immune system disorder—Prednisone—prostate cancer	0.000268	0.000481	CcSEcCtD
Deferoxamine—Eosinophilia—Doxorubicin—prostate cancer	0.000265	0.000477	CcSEcCtD
Deferoxamine—XDH—Metabolism—SULT1E1—prostate cancer	0.000265	0.00235	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—SRD5A1—prostate cancer	0.000265	0.00235	CbGpPWpGaD
Deferoxamine—Arrhythmia—Prednisone—prostate cancer	0.000265	0.000476	CcSEcCtD
Deferoxamine—Paraesthesia—Etoposide—prostate cancer	0.000264	0.000474	CcSEcCtD
Deferoxamine—Dyspnoea—Etoposide—prostate cancer	0.000262	0.00047	CcSEcCtD
Deferoxamine—Hypersensitivity—Mitoxantrone—prostate cancer	0.00026	0.000467	CcSEcCtD
Deferoxamine—Diarrhoea—Estradiol—prostate cancer	0.000259	0.000466	CcSEcCtD
Deferoxamine—Leukopenia—Capecitabine—prostate cancer	0.000259	0.000466	CcSEcCtD
Deferoxamine—Convulsion—Docetaxel—prostate cancer	0.000259	0.000466	CcSEcCtD
Deferoxamine—Infestation NOS—Epirubicin—prostate cancer	0.000258	0.000464	CcSEcCtD
Deferoxamine—Infestation—Epirubicin—prostate cancer	0.000258	0.000464	CcSEcCtD
Deferoxamine—Erythema—Prednisone—prostate cancer	0.000258	0.000463	CcSEcCtD
Deferoxamine—Myalgia—Docetaxel—prostate cancer	0.000255	0.000457	CcSEcCtD
Deferoxamine—Arthralgia—Docetaxel—prostate cancer	0.000255	0.000457	CcSEcCtD
Deferoxamine—Renal failure—Epirubicin—prostate cancer	0.000254	0.000456	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Etoposide—prostate cancer	0.000254	0.000456	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Epirubicin—prostate cancer	0.000253	0.000455	CcSEcCtD
Deferoxamine—XDH—Metabolism—HSD17B3—prostate cancer	0.000253	0.00225	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ACSL4—prostate cancer	0.000253	0.00225	CbGpPWpGaD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000253	0.000454	CcSEcCtD
Deferoxamine—Pain—Etoposide—prostate cancer	0.000251	0.000451	CcSEcCtD
Deferoxamine—Dizziness—Estradiol—prostate cancer	0.000251	0.00045	CcSEcCtD
Deferoxamine—Dysuria—Doxorubicin—prostate cancer	0.000251	0.00045	CcSEcCtD
Deferoxamine—Arthralgia—Capecitabine—prostate cancer	0.000247	0.000443	CcSEcCtD
Deferoxamine—Myalgia—Capecitabine—prostate cancer	0.000247	0.000443	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000245	0.00044	CcSEcCtD
Deferoxamine—Oedema—Docetaxel—prostate cancer	0.000244	0.000439	CcSEcCtD
Deferoxamine—Anaphylactic shock—Docetaxel—prostate cancer	0.000244	0.000439	CcSEcCtD
Deferoxamine—Vision blurred—Prednisone—prostate cancer	0.000243	0.000437	CcSEcCtD
Deferoxamine—Infection—Docetaxel—prostate cancer	0.000243	0.000436	CcSEcCtD
Deferoxamine—XDH—Metabolism—UMPS—prostate cancer	0.000242	0.00215	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PHGDH—prostate cancer	0.000242	0.00215	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ARG2—prostate cancer	0.000242	0.00215	CbGpPWpGaD
Deferoxamine—Diarrhoea—Mitoxantrone—prostate cancer	0.000242	0.000434	CcSEcCtD
Deferoxamine—Vomiting—Estradiol—prostate cancer	0.000241	0.000433	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Etoposide—prostate cancer	0.00024	0.000431	CcSEcCtD
Deferoxamine—Shock—Docetaxel—prostate cancer	0.00024	0.000431	CcSEcCtD
Deferoxamine—Nervous system disorder—Docetaxel—prostate cancer	0.000239	0.00043	CcSEcCtD
Deferoxamine—Thrombocytopenia—Docetaxel—prostate cancer	0.000239	0.000429	CcSEcCtD
Deferoxamine—Infestation NOS—Doxorubicin—prostate cancer	0.000239	0.000429	CcSEcCtD
Deferoxamine—Infestation—Doxorubicin—prostate cancer	0.000239	0.000429	CcSEcCtD
Deferoxamine—Tachycardia—Docetaxel—prostate cancer	0.000238	0.000428	CcSEcCtD
Deferoxamine—XDH—Metabolism—LDHB—prostate cancer	0.000238	0.00211	CbGpPWpGaD
Deferoxamine—Headache—Estradiol—prostate cancer	0.000237	0.000427	CcSEcCtD
Deferoxamine—Skin disorder—Docetaxel—prostate cancer	0.000237	0.000426	CcSEcCtD
Deferoxamine—Oedema—Capecitabine—prostate cancer	0.000236	0.000425	CcSEcCtD
Deferoxamine—Bradycardia—Epirubicin—prostate cancer	0.000236	0.000424	CcSEcCtD
Deferoxamine—Angioedema—Prednisone—prostate cancer	0.000236	0.000423	CcSEcCtD
Deferoxamine—Renal failure—Doxorubicin—prostate cancer	0.000235	0.000422	CcSEcCtD
Deferoxamine—Infection—Capecitabine—prostate cancer	0.000235	0.000422	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Doxorubicin—prostate cancer	0.000234	0.000421	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP3A5—prostate cancer	0.000233	0.00207	CbGpPWpGaD
Deferoxamine—Urticaria—Etoposide—prostate cancer	0.000233	0.000419	CcSEcCtD
Deferoxamine—Shock—Capecitabine—prostate cancer	0.000233	0.000418	CcSEcCtD
Deferoxamine—Body temperature increased—Etoposide—prostate cancer	0.000232	0.000417	CcSEcCtD
Deferoxamine—Abdominal pain—Etoposide—prostate cancer	0.000232	0.000417	CcSEcCtD
Deferoxamine—Nervous system disorder—Capecitabine—prostate cancer	0.000232	0.000416	CcSEcCtD
Deferoxamine—Thrombocytopenia—Capecitabine—prostate cancer	0.000231	0.000416	CcSEcCtD
Deferoxamine—Tachycardia—Capecitabine—prostate cancer	0.000231	0.000414	CcSEcCtD
Deferoxamine—Skin disorder—Capecitabine—prostate cancer	0.00023	0.000412	CcSEcCtD
Deferoxamine—Urinary tract disorder—Epirubicin—prostate cancer	0.000229	0.000411	CcSEcCtD
Deferoxamine—Hypotension—Docetaxel—prostate cancer	0.000228	0.00041	CcSEcCtD
Deferoxamine—Connective tissue disorder—Epirubicin—prostate cancer	0.000228	0.000409	CcSEcCtD
Deferoxamine—Urethral disorder—Epirubicin—prostate cancer	0.000227	0.000408	CcSEcCtD
Deferoxamine—XDH—Metabolism—PDHA1—prostate cancer	0.000225	0.002	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—TCN2—prostate cancer	0.000225	0.002	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—UCP3—prostate cancer	0.000225	0.002	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTA3—prostate cancer	0.000225	0.002	CbGpPWpGaD
Deferoxamine—Nausea—Estradiol—prostate cancer	0.000225	0.000404	CcSEcCtD
Deferoxamine—Vomiting—Mitoxantrone—prostate cancer	0.000225	0.000403	CcSEcCtD
Deferoxamine—Convulsion—Prednisone—prostate cancer	0.000224	0.000401	CcSEcCtD
Deferoxamine—Visual impairment—Epirubicin—prostate cancer	0.000223	0.000401	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000222	0.0004	CcSEcCtD
Deferoxamine—Headache—Mitoxantrone—prostate cancer	0.000221	0.000397	CcSEcCtD
Deferoxamine—Hypotension—Capecitabine—prostate cancer	0.000221	0.000397	CcSEcCtD
Deferoxamine—Myalgia—Prednisone—prostate cancer	0.00022	0.000395	CcSEcCtD
Deferoxamine—Arthralgia—Prednisone—prostate cancer	0.00022	0.000395	CcSEcCtD
Deferoxamine—Paraesthesia—Docetaxel—prostate cancer	0.000219	0.000394	CcSEcCtD
Deferoxamine—Bradycardia—Doxorubicin—prostate cancer	0.000218	0.000392	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000218	0.000392	CcSEcCtD
Deferoxamine—Dyspnoea—Docetaxel—prostate cancer	0.000218	0.000391	CcSEcCtD
Deferoxamine—Eye disorder—Epirubicin—prostate cancer	0.000217	0.000389	CcSEcCtD
Deferoxamine—Hypersensitivity—Etoposide—prostate cancer	0.000216	0.000389	CcSEcCtD
Deferoxamine—Tinnitus—Epirubicin—prostate cancer	0.000216	0.000388	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000215	0.000387	CcSEcCtD
Deferoxamine—XDH—Metabolism—HSD3B1—prostate cancer	0.000215	0.00191	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—SLC22A3—prostate cancer	0.000215	0.00191	CbGpPWpGaD
Deferoxamine—Paraesthesia—Capecitabine—prostate cancer	0.000212	0.000381	CcSEcCtD
Deferoxamine—Urinary tract disorder—Doxorubicin—prostate cancer	0.000212	0.00038	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000211	0.000379	CcSEcCtD
Deferoxamine—Connective tissue disorder—Doxorubicin—prostate cancer	0.000211	0.000379	CcSEcCtD
Deferoxamine—Dyspnoea—Capecitabine—prostate cancer	0.000211	0.000379	CcSEcCtD
Deferoxamine—Oedema—Prednisone—prostate cancer	0.000211	0.000378	CcSEcCtD
Deferoxamine—Anaphylactic shock—Prednisone—prostate cancer	0.000211	0.000378	CcSEcCtD
Deferoxamine—Angiopathy—Epirubicin—prostate cancer	0.00021	0.000378	CcSEcCtD
Deferoxamine—Urethral disorder—Doxorubicin—prostate cancer	0.00021	0.000378	CcSEcCtD
Deferoxamine—Nausea—Mitoxantrone—prostate cancer	0.00021	0.000377	CcSEcCtD
Deferoxamine—Immune system disorder—Epirubicin—prostate cancer	0.000209	0.000376	CcSEcCtD
Deferoxamine—Infection—Prednisone—prostate cancer	0.000209	0.000376	CcSEcCtD
Deferoxamine—Mediastinal disorder—Epirubicin—prostate cancer	0.000209	0.000375	CcSEcCtD
Deferoxamine—Pain—Docetaxel—prostate cancer	0.000209	0.000375	CcSEcCtD
Deferoxamine—Pruritus—Etoposide—prostate cancer	0.000208	0.000373	CcSEcCtD
Deferoxamine—Shock—Prednisone—prostate cancer	0.000207	0.000372	CcSEcCtD
Deferoxamine—Arrhythmia—Epirubicin—prostate cancer	0.000207	0.000372	CcSEcCtD
Deferoxamine—Visual impairment—Doxorubicin—prostate cancer	0.000207	0.000371	CcSEcCtD
Deferoxamine—Nervous system disorder—Prednisone—prostate cancer	0.000206	0.000371	CcSEcCtD
Deferoxamine—XDH—Metabolism—GSTA4—prostate cancer	0.000206	0.00183	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—TBXAS1—prostate cancer	0.000206	0.00183	CbGpPWpGaD
Deferoxamine—Tachycardia—Prednisone—prostate cancer	0.000205	0.000369	CcSEcCtD
Deferoxamine—Skin disorder—Prednisone—prostate cancer	0.000205	0.000367	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000204	0.000367	CcSEcCtD
Deferoxamine—Pain—Capecitabine—prostate cancer	0.000202	0.000363	CcSEcCtD
Deferoxamine—Erythema—Epirubicin—prostate cancer	0.000202	0.000362	CcSEcCtD
Deferoxamine—Diarrhoea—Etoposide—prostate cancer	0.000201	0.000361	CcSEcCtD
Deferoxamine—XDH—Metabolism—GSTA2—prostate cancer	0.000201	0.00178	CbGpPWpGaD
Deferoxamine—Eye disorder—Doxorubicin—prostate cancer	0.0002	0.00036	CcSEcCtD
Deferoxamine—Tinnitus—Doxorubicin—prostate cancer	0.0002	0.000359	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Docetaxel—prostate cancer	0.0002	0.000359	CcSEcCtD
Deferoxamine—XDH—Metabolism—ABCG5—prostate cancer	0.000198	0.00176	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—SULT1A1—prostate cancer	0.000198	0.00176	CbGpPWpGaD
Deferoxamine—Angiopathy—Doxorubicin—prostate cancer	0.000195	0.00035	CcSEcCtD
Deferoxamine—Dizziness—Etoposide—prostate cancer	0.000194	0.000349	CcSEcCtD
Deferoxamine—Muscle spasms—Epirubicin—prostate cancer	0.000194	0.000348	CcSEcCtD
Deferoxamine—XDH—Metabolism—GSTA1—prostate cancer	0.000194	0.00172	CbGpPWpGaD
Deferoxamine—Immune system disorder—Doxorubicin—prostate cancer	0.000194	0.000348	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Capecitabine—prostate cancer	0.000193	0.000347	CcSEcCtD
Deferoxamine—Mediastinal disorder—Doxorubicin—prostate cancer	0.000193	0.000347	CcSEcCtD
Deferoxamine—Body temperature increased—Docetaxel—prostate cancer	0.000193	0.000347	CcSEcCtD
Deferoxamine—Abdominal pain—Docetaxel—prostate cancer	0.000193	0.000347	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000192	0.000345	CcSEcCtD
Deferoxamine—XDH—Metabolism—HSD3B2—prostate cancer	0.000192	0.0017	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—NAT2—prostate cancer	0.000192	0.0017	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTO1—prostate cancer	0.000192	0.0017	CbGpPWpGaD
Deferoxamine—Arrhythmia—Doxorubicin—prostate cancer	0.000192	0.000344	CcSEcCtD
Deferoxamine—Vision blurred—Epirubicin—prostate cancer	0.00019	0.000342	CcSEcCtD
Deferoxamine—Paraesthesia—Prednisone—prostate cancer	0.000189	0.00034	CcSEcCtD
Deferoxamine—Urticaria—Capecitabine—prostate cancer	0.000188	0.000337	CcSEcCtD
Deferoxamine—Abdominal pain—Capecitabine—prostate cancer	0.000187	0.000336	CcSEcCtD
Deferoxamine—Body temperature increased—Capecitabine—prostate cancer	0.000187	0.000336	CcSEcCtD
Deferoxamine—Vomiting—Etoposide—prostate cancer	0.000187	0.000336	CcSEcCtD
Deferoxamine—Erythema—Doxorubicin—prostate cancer	0.000187	0.000335	CcSEcCtD
Deferoxamine—Headache—Etoposide—prostate cancer	0.000184	0.000331	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP2C18—prostate cancer	0.000184	0.00163	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PLCB2—prostate cancer	0.000184	0.00163	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—LRP2—prostate cancer	0.000184	0.00163	CbGpPWpGaD
Deferoxamine—Leukopenia—Epirubicin—prostate cancer	0.000181	0.000324	CcSEcCtD
Deferoxamine—XDH—Metabolism—P4HB—prostate cancer	0.00018	0.0016	CbGpPWpGaD
Deferoxamine—Hypersensitivity—Docetaxel—prostate cancer	0.00018	0.000323	CcSEcCtD
Deferoxamine—Muscle spasms—Doxorubicin—prostate cancer	0.000179	0.000322	CcSEcCtD
Deferoxamine—Vision blurred—Doxorubicin—prostate cancer	0.000176	0.000316	CcSEcCtD
Deferoxamine—XDH—Metabolism—SLC22A1—prostate cancer	0.000175	0.00156	CbGpPWpGaD
Deferoxamine—Convulsion—Epirubicin—prostate cancer	0.000175	0.000314	CcSEcCtD
Deferoxamine—Nausea—Etoposide—prostate cancer	0.000174	0.000313	CcSEcCtD
Deferoxamine—Hypersensitivity—Capecitabine—prostate cancer	0.000174	0.000313	CcSEcCtD
Deferoxamine—Pruritus—Docetaxel—prostate cancer	0.000173	0.00031	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Prednisone—prostate cancer	0.000172	0.000309	CcSEcCtD
Deferoxamine—Arthralgia—Epirubicin—prostate cancer	0.000172	0.000309	CcSEcCtD
Deferoxamine—Myalgia—Epirubicin—prostate cancer	0.000172	0.000309	CcSEcCtD
Deferoxamine—XDH—Metabolism—SULT2A1—prostate cancer	0.000171	0.00152	CbGpPWpGaD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000171	0.000306	CcSEcCtD
Deferoxamine—XDH—Metabolism—MED12—prostate cancer	0.000168	0.00149	CbGpPWpGaD
Deferoxamine—Urticaria—Prednisone—prostate cancer	0.000167	0.0003	CcSEcCtD
Deferoxamine—Pruritus—Capecitabine—prostate cancer	0.000167	0.0003	CcSEcCtD
Deferoxamine—Leukopenia—Doxorubicin—prostate cancer	0.000167	0.0003	CcSEcCtD
Deferoxamine—Diarrhoea—Docetaxel—prostate cancer	0.000167	0.0003	CcSEcCtD
Deferoxamine—XDH—Metabolism—GNG5—prostate cancer	0.000167	0.00148	CbGpPWpGaD
Deferoxamine—Abdominal pain—Prednisone—prostate cancer	0.000166	0.000299	CcSEcCtD
Deferoxamine—Body temperature increased—Prednisone—prostate cancer	0.000166	0.000299	CcSEcCtD
Deferoxamine—Oedema—Epirubicin—prostate cancer	0.000165	0.000296	CcSEcCtD
Deferoxamine—Anaphylactic shock—Epirubicin—prostate cancer	0.000165	0.000296	CcSEcCtD
Deferoxamine—Infection—Epirubicin—prostate cancer	0.000164	0.000294	CcSEcCtD
Deferoxamine—Shock—Epirubicin—prostate cancer	0.000162	0.000291	CcSEcCtD
Deferoxamine—Convulsion—Doxorubicin—prostate cancer	0.000162	0.000291	CcSEcCtD
Deferoxamine—Diarrhoea—Capecitabine—prostate cancer	0.000162	0.000291	CcSEcCtD
Deferoxamine—Nervous system disorder—Epirubicin—prostate cancer	0.000161	0.00029	CcSEcCtD
Deferoxamine—Dizziness—Docetaxel—prostate cancer	0.000161	0.00029	CcSEcCtD
Deferoxamine—Thrombocytopenia—Epirubicin—prostate cancer	0.000161	0.00029	CcSEcCtD
Deferoxamine—Tachycardia—Epirubicin—prostate cancer	0.000161	0.000289	CcSEcCtD
Deferoxamine—XDH—Metabolism—NCOA3—prostate cancer	0.000161	0.00143	CbGpPWpGaD
Deferoxamine—Skin disorder—Epirubicin—prostate cancer	0.00016	0.000287	CcSEcCtD
Deferoxamine—Myalgia—Doxorubicin—prostate cancer	0.000159	0.000285	CcSEcCtD
Deferoxamine—Arthralgia—Doxorubicin—prostate cancer	0.000159	0.000285	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000158	0.000284	CcSEcCtD
Deferoxamine—Dizziness—Capecitabine—prostate cancer	0.000156	0.000281	CcSEcCtD
Deferoxamine—Vomiting—Docetaxel—prostate cancer	0.000155	0.000279	CcSEcCtD
Deferoxamine—Hypersensitivity—Prednisone—prostate cancer	0.000155	0.000279	CcSEcCtD
Deferoxamine—Hypotension—Epirubicin—prostate cancer	0.000154	0.000276	CcSEcCtD
Deferoxamine—XDH—Metabolism—HPGDS—prostate cancer	0.000153	0.00136	CbGpPWpGaD
Deferoxamine—Headache—Docetaxel—prostate cancer	0.000153	0.000275	CcSEcCtD
Deferoxamine—Oedema—Doxorubicin—prostate cancer	0.000152	0.000274	CcSEcCtD
Deferoxamine—Anaphylactic shock—Doxorubicin—prostate cancer	0.000152	0.000274	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP2C19—prostate cancer	0.000152	0.00135	CbGpPWpGaD
Deferoxamine—Infection—Doxorubicin—prostate cancer	0.000151	0.000272	CcSEcCtD
Deferoxamine—Vomiting—Capecitabine—prostate cancer	0.00015	0.00027	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.00015	0.000269	CcSEcCtD
Deferoxamine—Shock—Doxorubicin—prostate cancer	0.00015	0.000269	CcSEcCtD
Deferoxamine—Nervous system disorder—Doxorubicin—prostate cancer	0.000149	0.000268	CcSEcCtD
Deferoxamine—Thrombocytopenia—Doxorubicin—prostate cancer	0.000149	0.000268	CcSEcCtD
Deferoxamine—Pruritus—Prednisone—prostate cancer	0.000149	0.000268	CcSEcCtD
Deferoxamine—Tachycardia—Doxorubicin—prostate cancer	0.000149	0.000267	CcSEcCtD
Deferoxamine—XDH—Metabolism—ACHE—prostate cancer	0.000149	0.00132	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTT1—prostate cancer	0.000149	0.00132	CbGpPWpGaD
Deferoxamine—Headache—Capecitabine—prostate cancer	0.000148	0.000266	CcSEcCtD
Deferoxamine—Skin disorder—Doxorubicin—prostate cancer	0.000148	0.000266	CcSEcCtD
Deferoxamine—Paraesthesia—Epirubicin—prostate cancer	0.000148	0.000266	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP2A6—prostate cancer	0.000147	0.0013	CbGpPWpGaD
Deferoxamine—Dyspnoea—Epirubicin—prostate cancer	0.000147	0.000264	CcSEcCtD
Deferoxamine—Nausea—Docetaxel—prostate cancer	0.000145	0.00026	CcSEcCtD
Deferoxamine—Diarrhoea—Prednisone—prostate cancer	0.000144	0.000259	CcSEcCtD
Deferoxamine—XDH—Metabolism—AKR1C3—prostate cancer	0.000143	0.00127	CbGpPWpGaD
Deferoxamine—Hypotension—Doxorubicin—prostate cancer	0.000142	0.000256	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000142	0.000255	CcSEcCtD
Deferoxamine—XDH—Metabolism—PRKACB—prostate cancer	0.000142	0.00126	CbGpPWpGaD
Deferoxamine—Pain—Epirubicin—prostate cancer	0.000141	0.000253	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP17A1—prostate cancer	0.000141	0.00125	CbGpPWpGaD
Deferoxamine—Nausea—Capecitabine—prostate cancer	0.00014	0.000252	CcSEcCtD
Deferoxamine—Dizziness—Prednisone—prostate cancer	0.000139	0.00025	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.000139	0.000249	CcSEcCtD
Deferoxamine—Paraesthesia—Doxorubicin—prostate cancer	0.000137	0.000246	CcSEcCtD
Deferoxamine—Dyspnoea—Doxorubicin—prostate cancer	0.000136	0.000244	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Epirubicin—prostate cancer	0.000135	0.000242	CcSEcCtD
Deferoxamine—XDH—Metabolism—NCOA2—prostate cancer	0.000134	0.00119	CbGpPWpGaD
Deferoxamine—Vomiting—Prednisone—prostate cancer	0.000134	0.00024	CcSEcCtD
Deferoxamine—Headache—Prednisone—prostate cancer	0.000132	0.000237	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000132	0.000236	CcSEcCtD
Deferoxamine—Urticaria—Epirubicin—prostate cancer	0.000131	0.000235	CcSEcCtD
Deferoxamine—Pain—Doxorubicin—prostate cancer	0.00013	0.000234	CcSEcCtD
Deferoxamine—Body temperature increased—Epirubicin—prostate cancer	0.00013	0.000234	CcSEcCtD
Deferoxamine—Abdominal pain—Epirubicin—prostate cancer	0.00013	0.000234	CcSEcCtD
Deferoxamine—XDH—Metabolism—SLC5A5—prostate cancer	0.000128	0.00114	CbGpPWpGaD
Deferoxamine—Nausea—Prednisone—prostate cancer	0.000125	0.000225	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP2E1—prostate cancer	0.000125	0.00111	CbGpPWpGaD
Deferoxamine—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000125	0.000224	CcSEcCtD
Deferoxamine—XDH—Metabolism—NQO1—prostate cancer	0.000124	0.0011	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—TH—prostate cancer	0.000122	0.00108	CbGpPWpGaD
Deferoxamine—Hypersensitivity—Epirubicin—prostate cancer	0.000121	0.000218	CcSEcCtD
Deferoxamine—Urticaria—Doxorubicin—prostate cancer	0.000121	0.000217	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP3A4—prostate cancer	0.00012	0.00107	CbGpPWpGaD
Deferoxamine—Body temperature increased—Doxorubicin—prostate cancer	0.00012	0.000216	CcSEcCtD
Deferoxamine—Abdominal pain—Doxorubicin—prostate cancer	0.00012	0.000216	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP1B1—prostate cancer	0.000118	0.00105	CbGpPWpGaD
Deferoxamine—Pruritus—Epirubicin—prostate cancer	0.000117	0.000209	CcSEcCtD
Deferoxamine—XDH—Metabolism—GGT1—prostate cancer	0.000115	0.00102	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—NCOA1—prostate cancer	0.000113	0.001	CbGpPWpGaD
Deferoxamine—Diarrhoea—Epirubicin—prostate cancer	0.000113	0.000202	CcSEcCtD
Deferoxamine—Hypersensitivity—Doxorubicin—prostate cancer	0.000112	0.000202	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP19A1—prostate cancer	0.000111	0.000989	CbGpPWpGaD
Deferoxamine—Dizziness—Epirubicin—prostate cancer	0.000109	0.000196	CcSEcCtD
Deferoxamine—Pruritus—Doxorubicin—prostate cancer	0.000108	0.000194	CcSEcCtD
Deferoxamine—XDH—Metabolism—RXRA—prostate cancer	0.000107	0.000954	CbGpPWpGaD
Deferoxamine—Vomiting—Epirubicin—prostate cancer	0.000105	0.000188	CcSEcCtD
Deferoxamine—Diarrhoea—Doxorubicin—prostate cancer	0.000104	0.000187	CcSEcCtD
Deferoxamine—XDH—Metabolism—COMT—prostate cancer	0.000104	0.000919	CbGpPWpGaD
Deferoxamine—Headache—Epirubicin—prostate cancer	0.000103	0.000185	CcSEcCtD
Deferoxamine—XDH—Metabolism—GSTP1—prostate cancer	0.000103	0.000915	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ITPR1—prostate cancer	0.000101	0.0009	CbGpPWpGaD
Deferoxamine—Dizziness—Doxorubicin—prostate cancer	0.000101	0.000181	CcSEcCtD
Deferoxamine—Nausea—Epirubicin—prostate cancer	9.78e-05	0.000176	CcSEcCtD
Deferoxamine—Vomiting—Doxorubicin—prostate cancer	9.69e-05	0.000174	CcSEcCtD
Deferoxamine—XDH—Metabolism—TYMS—prostate cancer	9.58e-05	0.00085	CbGpPWpGaD
Deferoxamine—Headache—Doxorubicin—prostate cancer	9.55e-05	0.000171	CcSEcCtD
Deferoxamine—XDH—Metabolism—GSTM1—prostate cancer	9.47e-05	0.000841	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—LPL—prostate cancer	9.29e-05	0.000825	CbGpPWpGaD
Deferoxamine—Nausea—Doxorubicin—prostate cancer	9.05e-05	0.000163	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP1A1—prostate cancer	8.98e-05	0.000797	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ERCC2—prostate cancer	8.9e-05	0.00079	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—MTHFR—prostate cancer	8.37e-05	0.000743	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PPARA—prostate cancer	8.21e-05	0.000729	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CAV1—prostate cancer	7.72e-05	0.000685	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CG—prostate cancer	7.03e-05	0.000624	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—INS—prostate cancer	6.65e-05	0.000591	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CREBBP—prostate cancer	6.52e-05	0.000579	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CD—prostate cancer	6.18e-05	0.000549	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—NOS3—prostate cancer	5.84e-05	0.000518	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CB—prostate cancer	5.39e-05	0.000478	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PTGS2—prostate cancer	5.34e-05	0.000474	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PTEN—prostate cancer	4.65e-05	0.000413	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—EP300—prostate cancer	4.44e-05	0.000394	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CA—prostate cancer	3.28e-05	0.000292	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—AKT1—prostate cancer	2.68e-05	0.000238	CbGpPWpGaD
